Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

MiNA Therapeutics Ltd.. (9/29/20). "Press Release: MiNA Therapeutics Appoints Peter Bains as Chief Business Officer". London.

Organisations Organisation MiNA Therapeutics Ltd.
  Organisation 2 Heptares Therapeutics Ltd. (Sosei Heptares)
  Group Sosei (Group)
Products Product small activating RNA therapeutic (saRNA)
  Product 2 pharmaceutical
Persons Person Bains, Peter (MiNA Therapeutics 202009– CBO before Sosei Heptares + Biocon/Syngene International + GSK)
  Person 2 Habib, Robert (MiNA Therapeutics Ltd 201705 CEO)

MiNA Therapeutics, the pioneer in RNAactivation therapeutics, announced today the appointment of Peter Bains as Chief Business Officer (CBO), effective September 22, 2020. Mr Bains currently serves on MiNA’s Board of Directors as Non Executive Director and will retain this position while joining MiNA’s senior leadership team. With more than three decades of experience in the global pharmaceutical industry, he will leverage his years of expertise to lead the Company’s business development and corporate strategy activities.

“Following the recent completion of our Series A financing, MiNA is well-positioned to both advance our clinical development efforts and expand our R&D pipeline to demonstrate the potential of saRNA therapeutics beyond liver cancer,” said Robert Habib, CEO of MiNA Therapeutics. “As an experienced biopharmaceutical industry executive, Peter's leadership capabilities, operational insight and existing understanding of the Company will be critical components to supporting the advancement of our company strategy and broaden the reach of saRNA therapeutics within the industry. We have benefited significantly from Peter’s contributions on the Board of Directors and are delighted to work more closely with him in this new executive role.”

“MiNA’s unique small activating RNA therapeutics have reached clinical validation and hold great promise as a new modality for the treatment of a range of diseases including cancer, metabolic and rare genetic diseases,” added Mr Peter Bains. “I am thrilled to join the accomplished team at MiNA Therapeutics and am looking forward to supporting the Company in its next stage of corporate and clinical development.”

Mr Bains bring to the role almost three decades of experience as a biopharmaceutical leader. Over a 23-year career at GSK, Mr Bains held multiple senior leadership roles in business development, commercial and general management. Subsequently he led Syngene International and Sosei Heptares as Chief Executive Officer. Since 2014 Mr Bains has worked closely with MiNA’s senior leadership as a Non Executive Director. He also serves as Non Executive Director for Indivior and Mereo BioPharma.

About MiNA Therapeutics

Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases.


MiNA Therapeutics
Robert Habib, CEO
Phone: +44 208 811 6700

Media requests:
Joanne Tudorica or Gretchen Schweitzer
Trophic Communications
Phone: +49 171 351 2733

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for MiNA Therapeutics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x300px

» top